Predicting Response to Immunotargeted Therapy in Endometrial Cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study

Predicting Response to Immunotargeted Therapy in Endometrial Cancer via Tumor Immune Microenvironment: A Multicenter, Observational Study

Only one-third of patients with advanced MSS/pMMR endometrial cancer exhibit a lasting response to the combination treatment of Pembrolizumab and Lenvatinib. The combined administration of these two drugs is based on Lenvatinib’s ability to modulate the tumor microenvironment, enabling Pembrolizumab...

Full description

Bibliographic Details
Main Authors: Anastasia Maltseva, Anna Kalinchuk, Nataliya Chernorubashkina, Virab Sisakyan, Igor Lots, Alina Gofman, Yulia Anzhiganova, Elizaveta Martynova, Ruslan Zukov, Elena Aleksandrova, Larisa Kolomiets, Liubov Tashireva
Format: Article
Language:English
Published: MDPI AG 2024-04-01
Series:International Journal of Molecular Sciences
Subjects:
endometrial cancer
immunotargeted therapy
tumor microenvironment
lymphocytes
Online Access:https://www.mdpi.com/1422-0067/25/7/3933

Similar Items

Similar Items